Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Depreciation and Depletion: 2022-2024

Historic Depreciation and Depletion for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $219,969.

  • Addex Therapeutics' Depreciation and Depletion rose 121.22% to $219,969 in Q4 2024 from the same period last year, while for Dec 2024 it was $459,360, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $295,679 for FY2024, which is 13.20% down from last year.
  • Per Addex Therapeutics' latest filing, its Depreciation and Depletion stood at $219,969 for Q4 2024, which was up 535.27% from $34,626 recorded in Q3 2024.
  • Addex Therapeutics' Depreciation and Depletion's 5-year high stood at $168.1 billion during Q2 2023, with a 5-year trough of $34,626 in Q3 2024.
  • Its 3-year average for Depreciation and Depletion is $14.0 billion, with a median of $84,276 in 2022.
  • As far as peak fluctuations go, Addex Therapeutics' Depreciation and Depletion spiked by 194,303,155.50% in 2023, and later slumped by 100.00% in 2024.
  • Quarterly analysis of 3 years shows Addex Therapeutics' Depreciation and Depletion stood at $78,524 in 2022, then rose by 26.63% to $99,433 in 2023, then soared by 121.22% to $219,969 in 2024.
  • Its last three reported values are $219,969 in Q4 2024, $34,626 for Q3 2024, and $127,520 during Q2 2024.